ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements
Dishman Carbogen Amcis Ltd fixed the record date for interest and partial redemption of its NCDs (ISIN: INE385W07059). The redemption totals ₹4.17 Crore.
Dishman Carbogen Amcis Ltd has made the sixth quarterly interest payment of ₹1.26 Crore on its non-convertible debentures as per Regulation 57(1).
Dishman Carbogen Amcis' subsidiary, Carbogen Amcis AG, successfully completed a US FDA inspection at its Vionnaz, Switzerland site without any observations.
Dishman Carbogen Amcis Ltd paid the first quarterly interest of ₹0.45 Crore on its Non-Convertible Debentures (ISIN: INE385W07067), complying with SEBI regulations.
Dishman Carbogen Amcis Ltd has fixed September 11, 2026, as the record date for the sixth quarterly interest payment on its non-convertible debentures.
Dishman Carbogen Amcis Ltd submitted the Notice of its 19th Annual General Meeting and the Annual Report for FY 2025-26. The AGM is scheduled for September 30, 2026.
Q1FY27 revenue fell 4.3% YoY to ₹6,776mn, with EBITDA margins dropping sharply to 8.9% due to CDMO project deferments and fixed costs.
Dishman Carbogen Amcis Ltd reported revenue from operations of ₹677.6 Cr (-4.3% YoY) and a net loss of ₹57.9 Cr for Q1 FY27.
Dishman Carbogen Amcis reported Q4 FY26 revenue of ₹851cr (up 19% YoY) and EBITDA of ₹163cr. Strategy focuses on high-margin ADC products and India site tech transfers.
Dishman Carbogen Amcis reported strong FY26 performance with revenue up 8.1% and EBITDA margins expanding to 19.3%. Growth is driven by CDMO and Vitamin D analogue segments.
Dishman Carbogen Amcis Ltd reported revenue from operations of ₹851.4 Cr (+18.9% YoY) and net profit of ₹21.7 Cr (-49.7% YoY) for Q4 FY26.